Red Flags Detected

  • Departure Of Cfo (new) — The Chief Financial Officer departed the company effective June 6, 2026.
NASDAQ: MIRA MIRA PHARMACEUTICALS, INC. 8-K

MIRA Pharmaceuticals CFO departs, replaced by fractional CFO at $6,000/month

Filed June 8, 2026 · Period ending June 2, 2026 · ~1 min read

Key Changes

  • high

    CFO Alan Weichselbaum departed June 6, 2026; company states departure was not due to any disagreement on operations, policies, or practices.

    Item 5.02 verify on EDGAR →
  • high

    Andriy Mushak appointed fractional CFO effective June 6, 2026, serving part-time through consulting firm LMAM rather than as full-time employee.

    Item 5.02 verify on EDGAR →
  • medium

    New CFO will be paid $6,000 per month via consulting agreement—significantly lower than typical full-time CFO compensation for a public company.

    Item 5.02 verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.

Partner

Trade MIRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · Jun 10, 2026 5:13 PM